Bristol-Myers Squibb has strengthened its links with Duke Translational Medicine Institute (DTMI), a leading university dedicated to healthcare research.
A newly-formed strategic relationship between the two organisations will lead to increased exchange of knowledge between DTMI's researchers and Bristol-Myers Squibb's scientists and project teams, building on decades of collaborations.
Having worked together in the fields of cardiology, endocrinology and oncology in the past, the bodies are now looking to expand into new areas, with the first joint project focusing on the development of a new idiopathic pulmonary fibrosis drug.
Elliott Sigal, executive vice-president, chief scientific officer and president of research and development at Bristol-Myers Squibb, said: "Our hope is that this partnership will allow the organisations to collaborate on projects involving all phases of research, development and disease education."
Last month, the company announced the provision of a series of grants to hepatitis projects in China and India, as part of its commitment to supporting global health initiatives.